ArticlePloS one2026
Multi-epitope vaccine design against Monkeypox virus: An immunoinformatics approach.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational immunoinformatics and molecular modeling approaches for designing a multi-epitope vaccine against Babesia microti.BMC microbiology · 2026Article
- mRNA vaccines against monkeypox: bridging immunoinformatics, structural vaccinology, and translational advances toward pan-orthopox immunity.Folia microbiologica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent outbreak of the Monkeypox virus (MPXV) across multiple regions has highlighted the need for effective vaccine. This study employed an in-silico immunoinformatics approach to design a multi-epitope vaccine against monkeypox virus.
methodsThe IMV heparin binding surface protein (H3L) of MPV was selected as vaccine target. B and T cell epitopes were predicted and evaluated for their toxicity, allergenicity, antigenicity and global population coverage. A multi-epitope construct was assembled using adjuvant and appropriate linkers. The 3D vaccine structure was modelled, enhanced and then checked for its overall structure and physiochemical properties. The in-silico docking vaccine construct and TLR3 receptor was performed to check affinity and stability of vaccine-TLR3 complex. The vaccine's ability to express and activate the immune system was demonstrated by its cloning into the E. coli plasmid pET-28b (+).
resultsThe selected H3L protein exhibited 92.22% sequence conservation across Monkeypox virus isolates of different continents, supporting its suitability as broad-spectrum vaccine target. The molecular docking and dynamics analysis confirmed both the stability and strong binding affinity of the vaccine construct with the TLR3. Immune stimulation predicted robust humoral and cellular responses, with evidence of immunological memory formation.
conclusionOverall, we proposed a potential vaccine construct that has the potential to effectively prevents monkeypox. However, in-vivo and in-vitro investigations are needed to validate the biological effectiveness and safety of the suggested vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.